Tag: chemistry
-
Environmental Biomarker Start-Up Gains $16M in Early Funds
A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds.
-
CEPI Assessing Advanced RNA Nanoparticle Vaccine
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics.
-
Nanotech Enzyme Process Boosts T-Cell Cancer Therapies
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells.
-
Biotech Alliance Creating Circular RNA Cancer Drug
A partnership of biotechnology components and therapy companies aims to develop new drugs made from circular forms of RNA, starting with a colorectal cancer treatment.
-
Protein Chemistry Biotech Gains Collaboration, Venture Funds
An enterprise discovering new drugs with optical light-based protein chemistry is emerging from stealth, including work with biopharmaceutical company Genentech.
-
Company Started for Gene Editing Rare Inherited Diseases
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells.
-
Over-the-Counter Naloxone Receiving Faster FDA Review
The opioid overdose drug naloxone in nasal spray form is receiving priority review from the Food and Drug Administration as an over-the-counter drug.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Food Protein Biotech Adds €4M in Seed Funds
A new company creating protein ingredients for food products from carbon dioxide converted by engineered bacteria is raising €4 million more in seed funds.
-
Cell Biology Tools Companies Merge in $57.8M Deal
Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation.